“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

Body size and excess weight, conventionally assessed using body mass index (BMI), are well-established risk factors for many types of cancer. However, new research to be presented at this year’s ...

"You could say that allergic disease is a systemic and inflammatory condition," said Joks, who is both chief of the division ...

Mylan N.V. (MYL +0.5%) announces the U.S. commercial launch of perphenazine tablets, the generic version of Merck (NYSE:MRK)'s ...

By Tamara Mathias (Reuters) - Merck & Co's (N:MRK) blockbuster drug Keytruda helped previously untreated lung cancer ...

Merck (MRK) ended the recent trading session at $94.02, demonstrating a -0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.08%.

Merck’s stock price slipped 0.74% to $94.02, lagging behind the broader market’s gains. This dip came despite Merck ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

Merck & Co. is making waves as an undervalued S&P 500 stock, boasting a forward P/E ratio of 10.52 and strong hedge fund ...

Reports Q4 sales $667.1M, consensus $674.52M. Comparable store sales increased 2.8% from the prior year increase of 3.9%.”We were very pleased ...